 | |
| Clinical data | |
|---|---|
| Trade names | Prevymis |
| Other names | AIC246; MK-8228 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618006 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth, intravenous |
| Drug class | Antiviral |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 37% (estimate) |
| Protein binding | 98.2% |
| Metabolism | glucuronidation (UGT1A1/1A3) to a minor extent |
| Elimination half-life | 12 hours |
| Excretion | 93.3% via faeces, <2% via kidneys |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C29H28F4N4O4 |
| Molar mass | 572.561 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Letermovir, sold under the brand name Prevymis, is an antiviral medication used to prevent cytomegalovirus (CMV) reactivation following allogeneic stem cell transplant.[1] It is used in those who are seropositive for CMV.[1] It may be taken by mouth or injection into a vein.[3]
Common side effects include nausea, diarrhea, and vomiting.[2] Other side effects may include swelling, cough, headache, and tiredness.[3] It is a cytomegalovirus DNA terminase complex inhibitor.[1]
Letermovir was approved for medical use in the United States in 2017 and Europe in 2018.[3][2] In the United Kingdom it costs the NHS about £7,500 for 4 weeks as of 2021.[1] This amount in the United States is about 6,200 USD.[4]
References
edit- ^ a b c d e f BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 679. ISBN 978-0857114105.
- ^ a b c "Prevymis". Archived from the original on 12 July 2021. Retrieved 21 November 2021.
- ^ a b c "Letermovir Monograph for Professionals". Drugs.com. Archived from the original on 22 April 2021. Retrieved 21 November 2021.
- ^ "Prevymis Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 21 November 2021.